CL2007002745A1 - Acido nucleico quimerico que comprende una secuencia codificante para la proteina tgf-beta3; y metodo para la expresion de tgf-beta3 en una planta. - Google Patents

Acido nucleico quimerico que comprende una secuencia codificante para la proteina tgf-beta3; y metodo para la expresion de tgf-beta3 en una planta.

Info

Publication number
CL2007002745A1
CL2007002745A1 CL200702745A CL2007002745A CL2007002745A1 CL 2007002745 A1 CL2007002745 A1 CL 2007002745A1 CL 200702745 A CL200702745 A CL 200702745A CL 2007002745 A CL2007002745 A CL 2007002745A CL 2007002745 A1 CL2007002745 A1 CL 2007002745A1
Authority
CL
Chile
Prior art keywords
beta3
tgf
expression
plant
nucleic acid
Prior art date
Application number
CL200702745A
Other languages
English (en)
Inventor
Mark William James Me Ferguson
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of CL2007002745A1 publication Critical patent/CL2007002745A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8214—Plastid transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
CL200702745A 2006-09-11 2007-09-24 Acido nucleico quimerico que comprende una secuencia codificante para la proteina tgf-beta3; y metodo para la expresion de tgf-beta3 en una planta. CL2007002745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0617816.4A GB0617816D0 (en) 2006-09-11 2006-09-11 Nucleic acids and methods of protein expression

Publications (1)

Publication Number Publication Date
CL2007002745A1 true CL2007002745A1 (es) 2008-10-03

Family

ID=37232698

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702745A CL2007002745A1 (es) 2006-09-11 2007-09-24 Acido nucleico quimerico que comprende una secuencia codificante para la proteina tgf-beta3; y metodo para la expresion de tgf-beta3 en una planta.

Country Status (12)

Country Link
US (1) US20090328250A1 (es)
EP (1) EP2074217A1 (es)
JP (1) JP2010502237A (es)
CN (1) CN101535484A (es)
AR (1) AR062749A1 (es)
AU (1) AU2007295983A1 (es)
BR (1) BRPI0716802A2 (es)
CA (1) CA2663146A1 (es)
CL (1) CL2007002745A1 (es)
GB (1) GB0617816D0 (es)
TW (1) TW200829697A (es)
WO (1) WO2008032035A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604964D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604966D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
JP2024513542A (ja) * 2021-01-04 2024-03-26 ティアマト サイエンシーズ 植物由来の合成生成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051848A (en) * 1976-03-01 1977-10-04 Levine Norman S Synthetic skin wound dressing
US6559123B1 (en) * 1985-04-19 2003-05-06 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
EP0914168A1 (en) * 1996-05-03 1999-05-12 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
EP1074620A1 (en) * 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
CA2344269A1 (en) * 1998-10-07 2000-04-13 Syngenta Participations Ag Therapeutically active proteins in plants
AR027765A1 (es) * 2000-04-03 2003-04-09 Monsanto Technology Llc Expresion y purificacion de polipeptidos bioactivos autenticos a partir de plantas
DE60127113T2 (de) * 2000-04-25 2007-06-14 Otsuka Pharmaceutical Co., Ltd. Gd3-mimetische peptide
US20040078851A1 (en) * 2000-05-02 2004-04-22 Ning Huang Production of human growth factors in monocot seeds
US20030033637A1 (en) * 2001-06-05 2003-02-13 Croptech Corporation Gene expression and production of TGF-beta proteins including bioactive mullerian inhibiting substance from plants
KR20050054928A (ko) * 2002-09-27 2005-06-10 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아 피자식물의 유전자 형질전환 식물의 생산용 벡터
WO2006118617A2 (en) * 2004-12-23 2006-11-09 Chlorogen, Inc. EXPRESSING TGF-β PROTEINS IN PLANT PLASTIDS
WO2007007095A2 (en) * 2005-07-12 2007-01-18 Renovo Ltd Pharmaceutical compositions comprising a tgf-beta superfamily member

Also Published As

Publication number Publication date
CA2663146A1 (en) 2008-03-20
GB0617816D0 (en) 2006-10-18
US20090328250A1 (en) 2009-12-31
TW200829697A (en) 2008-07-16
AU2007295983A1 (en) 2008-03-20
AR062749A1 (es) 2008-12-03
BRPI0716802A2 (pt) 2013-10-22
WO2008032035A1 (en) 2008-03-20
CN101535484A (zh) 2009-09-16
EP2074217A1 (en) 2009-07-01
JP2010502237A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
CL2012000877A1 (es) Acido nucleico que codifica variantes mutadas o truncas de la proteina cenh3, y metodo para generar una planta haploide.
BRPI0822756A2 (pt) sistema de prótese de válvula cardíaca e processo para produzir prótese de válvula cardíaca.
CL2007002070A1 (es) Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
CL2009000211A1 (es) Molécula de ácido nucleico que comprende una secuencia de direccionamiento a vacuola de almacenamiento de un polipéptido heterologo; y procedimiento para la acumulacion de dichas proteinas en una planta.
CL2011003184A1 (es) Polipéptido aislado que comprende un segmento de toxina de núcleo insecticida cry dig-11, método para controlar una peste en plantas basado en la aplicacion de dicho polipeptido; ácido nucleico que lo codifica y vector que comprende dicho polinicleotido.
BRPI0811883A2 (pt) Método e sistema para planejamento dentário.
BRPI0917353A2 (pt) método e sistema para a produção otimizada de gnl.
BRPI0813914A2 (pt) Sistema, e, método.
BRPI0822078A2 (pt) Método, e, sistema.
BRPI0814582A2 (pt) Dispositivo, método, e, usos de um método, e da quantidade de ácidos nucleicos virais totais.
BRPI0815494A2 (pt) Método implementado por computador, e, sistema.
DK2617823T3 (da) Phytaser, nukleinsyrer, der koder for disse, og fremgangsmåde til fremstilling og anvendelse heraf
BRPI0718971A2 (pt) Sistema para medir parâmetros, e, método para montar um sistema para medir parâmetros
BRPI0817811A2 (pt) Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas.
BRPI0822004A2 (pt) Sistema de freio e processo para o controle de um sistema de freio.
BRPI0812807A2 (pt) Método para a produção de um medicamento que contem tadafila
IL194479A0 (en) Plant virus-based inducible expression system
NL2003256A1 (nl) Optical element for a lithographic apparatus, lithographic apparatus comprising such optical element and method for making the optical element.
BRPI0816151A2 (pt) válvula utilizável com um poço, sistema usável com um poço, e método usável com um poço
BRPI0810190A2 (pt) Sistema, e, método.
BRPI0820898A2 (pt) Método, produto de programa de computador, e, sistema
BRPI0820122A2 (pt) Método de otimização de produção de poços, sistema, e método.
CL2012000553A1 (es) Un método para la producción de un promotor de planta especifico de semillas, constructo que contiene dicho promotor mejorado, vector y célula huésped que lo comprende.
CL2012001628A1 (es) Célula de planta que comprende adn que codifica para las pplantas vip3ab y cry1ca, metodo para manejar el desarrollo de resistencia a una proteina cry en un insecto.
BRPI0921831A2 (pt) Composição para controlar doenças de planta e método para controlar doenças de planta.